Table 1.
Comparison of clinical characteristics of ETR and LTR patients in the purely local recurrence group.
| Characteristic | Total | ETR group | LTR group | P-value |
|---|---|---|---|---|
| (n = 409)% | (n = 192)% | (n = 217)% | ||
| Age (years) | 0.203 | |||
| ≤46 years | 199 (48.7) | 87 (45.3) | 112 (51.6) | |
| >46 years | 210 (51.3) | 105 (54.7) | 105 (48.4) | |
| Gender | 0.282 | |||
| Male | 303 (74.1) | 147 (76.6) | 156 (71.9) | |
| Female | 106 (25.9) | 45 (23.4) | 61 (28.1) | |
| Smoking status | 0.535 | |||
| Non-smoker | 243 (59.4) | 111 (57.8) | 132 (60.8) | |
| Smoker | 166 (40.6) | 81 (42.2) | 85 (39.2) | |
| Alcohol abuse | 0.804 | |||
| Non-drinker | 368 (90.0) | 172 (89.6) | 196 (90.3) | |
| Drinker | 41 (10.0) | 20 (10.4) | 21 (9.7) | |
| Tumor family history | 0.410 | |||
| No | 308 (75.3) | 141 (73.4) | 167 (77.0) | |
| Yes | 101 (24.7) | 51 (26.6) | 50 (23.0) | |
| Cranial nerve symptom | 0.741 | |||
| N0 | 356 (87.0) | 166 (86.5) | 190 (87.6) | |
| Yes | 53 (13.0) | 26 (13.5) | 27 (12.4) | |
| Baseline value of EBV-DNA | 0.212 | |||
| ≤2,000 | 189 (46.2) | 95 (49.5) | 94 (43.3) | |
| >2,000 | 220 (53.8) | 97 (50.5) | 123 (56.7) | |
| Histological type | 0.218 | |||
| WHO I/II | 18 (4.4) | 11 (5.7) | 7 (3.2) | |
| WHO III | 391 (95.6) | 181 (94.3) | 210 (96.8) | |
| T stage | 0.084 | |||
| 1/2 | 60 (14.7) | 22 (11.5) | 38 (17.5) | |
| 3/4 | 349 (85.3) | 170 (88.5) | 179 (82.5) | |
| N stage | 0.258 | |||
| 0/1 | 274 (67.0) | 134 (69.8) | 140 (64.5) | |
| 2/3 | 135 (33.0) | 58 (30.2) | 77 (35.5) | |
| TNM stage | 0.416 | |||
| I/II | 46 (11.2) | 19 (9.9) | 27 (12.4) | |
| III/IV | 363 (88.8) | 173 (90.1) | 190 (87.6) | |
| Induction chemotherapy | 0.927 | |||
| No | 195 (47.7) | 92 (47.9) | 103 (47.5) | |
| Yes | 214 (52.3) | 100 (52.1) | 252 (52.5) | |
| Concurrent chemotherapy | 0.171 | |||
| No | 86 (21.0) | 46 (24.0) | 40 (18.4) | |
| Yes | 323 (79.0) | 146 (76.0) | 17781.6) | |
| Adjuvant chemotherapy | 0.404 | |||
| No | 388 (94.9) | 184 (95.8) | 204 (94.0) | |
| Yes | 21 (5.1) | 8 (4.2) | 13 (6.0) | |
| Post-recurrence treatment options | 0.073 | |||
| BST | 47 (11.5) | 26 (13.5) | 21 (9.7) | |
| Salvage surgery | 19 (4.7) | 8 (4.2) | 11 (5.1) | |
| Re-irradiation | 203 (49.6) | 83 (43.2) | 120 (55.3) | |
| Chemotherapy | 140 (34.2) | 75 (39.1) | 65 (29.9) | |